MedDataX Logo

Epidemiological Study in FRONtoTemporal Dementia

NCT ID: NCT05075187

Last Updated: 2023-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

4500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-09-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An international, multicenter, epidemiological observational study aims to investigate the prevalence of genetic etiologies in patients diagnosed with FTD or clinically suspected for FTD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Frontotemporal dementia (FTD) is a genetically and pathologically heterogeneous neurodegenerative disease caused by the loss or damage of nerve cells in the brain's frontal and temporal lobes. This leads to abnormalities in behaviour, personality, and language comprehension problems. Also, people with FTD show movement disorders like tremor, rigidity, difficulty in coordination, muscle spasms and weakness. FTD's etiology is sporadic or heritable. Sixty to 70% of FTD cases are sporadic, while 30 to 40% are inherited (familial aggregation). For this study, blood samples were collected from clinically diagnosed or suspected FTD patients and were analysed for a broad range of pathogenic variants in genes associated with FTD. The scientific insights acquired from this study will help identify novel therapeutic targets and develop/ investigate potential disease-modifying drugs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Frontotemporal Dementia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Participants diagnosed with Frontotemporal Dementia

Participants diagnosed with Frontotemporal Dementia

Genetic Screening

Intervention Type DIAGNOSTIC_TEST

Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Genetic Screening

Blood samples will be collected from clinically diagnosed or suspected FTD patients and will be analysed for a broad range of pathogenic variants in genes associated with FTD.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent, which includes reference to the genetic testing, is obtained from the participant/legal guardian
* The participant is aged between 25 to 85 years
* The participant is diagnosed with Frontotemporal dementia (FTD) or has signs or symptoms of FTD
Minimum Eligible Age

25 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CENTOGENE GmbH Rostock

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Peter Bauer, Ph.D

Role: PRINCIPAL_INVESTIGATOR

Centogene GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

AZ Damiaan

Ostend, West Flanders, Belgium

Site Status

CHU de Liege

Liège, , Belgium

Site Status

Hanau Hospital

Hanau, Hesse, Germany

Site Status

Gertrudis Klinik

Leun, Hesse, Germany

Site Status

University Hospital Dresden

Dresden, Saxony, Germany

Site Status

University Medical Center Hamburg Eppendorf

Hamburg, Schleswig-Holstein, Germany

Site Status

University of Lübeck

Lübeck, Schleswig-Holstein, Germany

Site Status

RWTH Aachen University

Aachen, , Germany

Site Status

Hochtaunus-Kliniken gGmbH

Bad Homburg, , Germany

Site Status

AGZ of Charite Universitätsmedizin Berlin

Berlin, , Germany

Site Status

University Hospital Cologne

Cologne, , Germany

Site Status

Asklepios Klinik Nord - Ochsenzoll

Hamburg, , Germany

Site Status

University Hospital Rostock

Rostock, , Germany

Site Status

Mediterraneo Hospital

Athens, , Greece

Site Status

University of Ioannina

Ioannina, , Greece

Site Status

Università degli studi Gabriele D'Annunzio Chieti-Pescara

Chieti, , Italy

Site Status

Azienda Ospedaliera Universitaria Federico II di Napoli

Napoli, , Italy

Site Status

Azienda Ospedaliero-Universitaria di Parma

Parma, , Italy

Site Status

Azienda USL-IRCCS of Reggio Emilia

Reggio Emilia, , Italy

Site Status

Hospital Garcia de Orta

Almada, , Portugal

Site Status

Unidade Psiquiatrica Privada de Coimbra

Coimbra, , Portugal

Site Status

Hospital da Senhora da Oliveira Guimaraes

Guimarães, , Portugal

Site Status

Hospital Beatriz Ângelo

Loures, , Portugal

Site Status

Hospital Pedro Hispano

Matosinhos Municipality, , Portugal

Site Status

CNS - campus neurológico Torres Vedras

Torres Vedras, , Portugal

Site Status

Hospital Universitari vall D´hebron

Barcelona, , Spain

Site Status

Universitary Hospital La Princesa

Madrid, , Spain

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre

Madrid, , Spain

Site Status

Clinica Universidad de Navarra

Pamplona, , Spain

Site Status

Marqués de Valdecilla University Hospital

Santander, , Spain

Site Status

Baskent University

Ankara, , Turkey (Türkiye)

Site Status

Hacettepe University

Ankara, , Turkey (Türkiye)

Site Status

Koç University Hospital

Istanbul, , Turkey (Türkiye)

Site Status

Istanbul University

Istanbul, , Turkey (Türkiye)

Site Status

Bezmialem Vakif University

Istanbul, , Turkey (Türkiye)

Site Status

Izmir Economy University Medikalpark Hospital

Izmir, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Germany Greece Italy Portugal Spain Turkey (Türkiye)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EFRONT 05-2021

Identifier Type: -

Identifier Source: org_study_id